NewAmsterdam Pharma (NAMS) versus Its Rivals Head-To-Head Review

NewAmsterdam Pharma (NASDAQ:NAMS) is one of 1,077 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare NewAmsterdam Pharma to related businesses based on the strength of its dividends, institutional ownership, valuation, profitability, risk, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and price targets for NewAmsterdam Pharma and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	0	0	6	0	3.00
NewAmsterdam Pharma Competitors	8799	22838	51249	1429	2.54

NewAmsterdam Pharma presently has a consensus price target of $42.86, indicating a potential upside of 121.03%. As a group, “Pharmaceutical preparations” companies have a potential upside of 2,490.30%. Given NewAmsterdam Pharma’s peers higher possible upside, analysts clearly believe NewAmsterdam Pharma has less favorable growth aspects than its peers.

Risk & Volatility

NewAmsterdam Pharma has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma’s peers have a beta of 4.26, suggesting that their average stock price is 326% more volatile than the S&P 500.

Valuation & Earnings

This table compares NewAmsterdam Pharma and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NewAmsterdam Pharma	$47.14 million	-$176.94 million	-10.31
NewAmsterdam Pharma Competitors	$9.91 billion	$136.15 million	-5.32

NewAmsterdam Pharma’s peers have higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 20.8% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares NewAmsterdam Pharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	N/A	N/A	N/A
NewAmsterdam Pharma Competitors	-3,399.87%	-235.11%	-32.77%

Summary

NewAmsterdam Pharma beats its peers on 7 of the 13 factors compared.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.